SM1
MCID: SCH060
MIFTS: 39

Schistosoma Mansoni Infection, Susceptibility/ (SM1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosoma Mansoni Infection, Susceptibility/

MalaCards integrated aliases for Schistosoma Mansoni Infection, Susceptibility/:

Name: Schistosoma Mansoni Infection, Susceptibility/ 56
Schistosoma Mansoni Infection, Susceptibility/resistance to 56 13
Schistosomiasis 58 71
Sm1 56 17
Schistosoma Mansoni, Intensity of Infection by; Sm1 56
Schistosoma Mansoni, Intensity of Infection by 56
Bilharziasis 58

Characteristics:

Orphanet epidemiological data:

58
schistosomiasis
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
schistosoma mansoni infection, susceptibility/:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM 56 181460
MESH via Orphanet 44 D012552
ICD10 via Orphanet 33 B65.0 B65.1 B65.2 more
UMLS via Orphanet 72 C0036323
Orphanet 58 ORPHA1247
MedGen 41 C1866993
SNOMED-CT via HPO 68 263681008
UMLS 71 C0036323

Summaries for Schistosoma Mansoni Infection, Susceptibility/

MalaCards based summary : Schistosoma Mansoni Infection, Susceptibility/, also known as schistosoma mansoni infection, susceptibility/resistance to, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosoma Mansoni Infection, Susceptibility/ is SM1 (Schistosoma Mansoni, Susceptibility/Resistance To). The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotype is abnormality of the immune system.

More information from OMIM: 181460

Related Diseases for Schistosoma Mansoni Infection, Susceptibility/

Diseases related to Schistosoma Mansoni Infection, Susceptibility/ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 578)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 13.0
2 urinary schistosomiasis 12.8
3 pulmonary arterial hypertension associated with schistosomiasis 12.4
4 cercarial dermatitis 12.2
5 neuroschistosomiasis 11.7
6 hepatic fibrosis, severe due to schistosoma mansoni infection 11.2
7 portal hypertension 10.9
8 splenomegaly 10.8
9 varicose veins 10.7
10 bladder cancer 10.7
11 hypereosinophilic syndrome 10.6
12 parasitic helminthiasis infectious disease 10.6
13 liver cirrhosis 10.6
14 esophageal varix 10.6
15 fibrosis of extraocular muscles, congenital, 1 10.6
16 pulmonary hypertension 10.5
17 diarrhea 10.5
18 filariasis 10.5
19 allergic hypersensitivity disease 10.5
20 appendicitis 10.5
21 malaria 10.4
22 hepatitis b 10.4
23 fascioliasis 10.4
24 liver disease 10.4
25 hepatitis c 10.4
26 small cell carcinoma 10.4
27 infertility 10.4
28 paragonimiasis 10.4
29 viral hepatitis 10.4
30 myelitis 10.4
31 pulmonary hypertension, primary, 1 10.4
32 ancylostomiasis 10.3
33 filarial elephantiasis 10.3
34 clonorchiasis 10.3
35 urinary tract obstruction 10.3
36 cytokine deficiency 10.3
37 hydronephrosis 10.3
38 onchocerciasis 10.3
39 cystitis 10.3
40 glomerulonephritis 10.3
41 transverse myelitis 10.3
42 hepatocellular carcinoma 10.3
43 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
44 kala-azar 1 10.3
45 leishmaniasis 10.3
46 salmonellosis 10.3
47 strongyloidiasis 10.3
48 hypersplenism 10.3
49 colorectal cancer 10.3
50 hepatitis c virus 10.3

Graphical network of the top 20 diseases related to Schistosoma Mansoni Infection, Susceptibility/:



Diseases related to Schistosoma Mansoni Infection, Susceptibility/

Symptoms & Phenotypes for Schistosoma Mansoni Infection, Susceptibility/

Human phenotypes related to Schistosoma Mansoni Infection, Susceptibility/:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 31 HP:0002715

Symptoms via clinical synopsis from OMIM:

56
Immunology:
schistosoma mansoni infection susceptibility/resistance

Clinical features from OMIM:

181460

Drugs & Therapeutics for Schistosoma Mansoni Infection, Susceptibility/

Drugs for Schistosoma Mansoni Infection, Susceptibility/ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lumefantrine Approved Phase 4 82186-77-4 6437380
2
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
3 Artemether, Lumefantrine Drug Combination Phase 4
4
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
5
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
6
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
7
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
8
leucovorin Approved Phase 3 58-05-9 6006 143
9
Triclabendazole Approved, Investigational Phase 3 68786-66-3
10
Tranexamic Acid Approved Phase 3 1197-18-8 5526
11
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
12
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
13
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
14
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
15
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
18
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
19 Iron Supplement Phase 3
20 Trace Elements Phase 3
21 Micronutrients Phase 3
22 Vitamins Phase 3
23 Hematinics Phase 3
24 Nutrients Phase 3
25 Fanasil, pyrimethamine drug combination Phase 3
26 Antiprotozoal Agents Phase 3
27 Tubulin Modulators Phase 3
28 Antimitotic Agents Phase 3
29 Vitamin B Complex Phase 3
30 Folic Acid Antagonists Phase 3
31 Sulfalene Phase 3
32 Folate Phase 3
33 Vitamin B9 Phase 3
34 Hemostatics Phase 3
35 Antifibrinolytic Agents Phase 3
36 Coagulants Phase 3
37 Dermatologic Agents Phase 2, Phase 3
38 Antimalarials Phase 3
39 Antiviral Agents Phase 3
40 Artemisinine Phase 3
41 Artemisinins Phase 3
42
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
43
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
44
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 6474909
45
Indian frankincense Approved, Experimental, Investigational Phase 1, Phase 2
46
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
47
Pyronaridine Investigational Phase 2 74847-35-1 5485198
48
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795
49
Uric acid Investigational Phase 1, Phase 2 69-93-2 1175
50 Vaccines Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
7 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
8 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Completed NCT04115072 Phase 2, Phase 3 Praziquantel 600Mg Oral Tablet x 5;Praziquantel 600Mg Oral Tablet x 1
12 Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children Completed NCT01054651 Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamine;Praziquantel
13 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
14 Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial Completed NCT01658124 Phase 3 Tranexamic Acid;Placebo
15 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
16 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
17 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
18 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
19 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
20 Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II Unknown status NCT01718834 Phase 1, Phase 2
21 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
22 Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection Completed NCT04264130 Phase 2 Artesunate-Pyronaridine;Artemether-Lumefantrine;Artefenomel-Ferroquine
23 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
24 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Completed NCT03799510 Phase 2 GLA-SE solution
25 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
26 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
27 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
28 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Recruiting NCT03910972 Phase 1, Phase 2
29 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
30 Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms Not yet recruiting NCT04407507 Phase 2 Ivermectin;Placebo
31 Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial Not yet recruiting NCT03924596 Phase 1, Phase 2 AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate
32 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
33 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
34 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
35 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Completed NCT03110757 Phase 1
36 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
37 Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development Completed NCT03361163 Phase 1
38 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
39 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
40 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
41 The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study) Unknown status NCT02329314
42 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
43 ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C Unknown status NCT02826447
44 The Effect of Biscuits Containing Red Palm Oil on School Children With Vitamin A Deficiency in West and East Malaysia Unknown status NCT03256123
45 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
46 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
47 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
48 Detection of Schistosomiasis Circulating Anodic Antigen (CAA) in Travellers After High-risk Water Contact Completed NCT02194712
49 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
50 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307

Search NIH Clinical Center for Schistosoma Mansoni Infection, Susceptibility/

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Praziquantel

Genetic Tests for Schistosoma Mansoni Infection, Susceptibility/

Anatomical Context for Schistosoma Mansoni Infection, Susceptibility/

MalaCards organs/tissues related to Schistosoma Mansoni Infection, Susceptibility/:

40
Liver, Testes, T Cells, Colon, Spinal Cord, Spleen, Skin

Publications for Schistosoma Mansoni Infection, Susceptibility/

Articles related to Schistosoma Mansoni Infection, Susceptibility/:

(show top 50) (show all 16275)
# Title Authors PMID Year
1
Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. 56 61
10441577 1999
2
Absence of linkage between MHC and a gene involved in susceptibility to human schistosomiasis. 61 56
9698772 1998
3
Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 56 61
8841190 1996
4
Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. 56 61
1902058 1991
5
Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. 56
21059925 2010
6
Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. 56
16301741 2005
7
Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 56
10094195 1999
8
Further evidence suggesting the presence of a locus, on human chromosome 5q31-q33, influencing the intensity of infection with Schistosoma mansoni. 56
9311752 1997
9
The essential schistosome tegumental ectoenzyme SmNPP5 can block NAD-induced T cell apoptosis. 61
32441549 2020
10
Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies. 61
32389835 2020
11
Towards deorphanizing G protein-coupled receptors of Schistosoma mansoni using the MALAR yeast two-hybrid system. 61
31840628 2020
12
Awareness of European practitioners toward uncommon tropical diseases: are we prepared to deal with mass migration? Results of an international survey. 61
31538244 2020
13
Role of adenylate kinase 1 in the integument development of Schistosoma japonicum schistosomula. 61
32277925 2020
14
Identification of Schistosoma japonicum GSK3β interacting partners by yeast two-hybrid screening and its role in parasite survival. 61
32500370 2020
15
Schistosomiasis Control: Leave No Age Group Behind. 61
32430274 2020
16
Urogenital Schistosomiasis in Fisherman, Nepal, 2019. 61
32568055 2020
17
Could This Child Have Schistosomiasis?: When to Suspect It and What to Do About It. 61
32379203 2020
18
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes. 61
32424554 2020
19
Cattle as natural host for Schistosoma haematobium (Bilharz, 1852) Weinland, 1858 x Schistosoma bovis Sonsino, 1876 interactions, with new cercarial emergence and genetic patterns. 61
32468189 2020
20
Parasite-derived circulating microRNAs as biomarkers for the detection of human Schistosoma japonicum infection. 61
31840631 2020
21
Evaluation of a rapid diagnostic test for Schistosoma mansoni infection based on the detection of circulating cathodic antigen in urine in Central Sudan. 61
32559192 2020
22
Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration. 61
32418795 2020
23
Multihost Transmission of Schistosoma mansoni in Senegal, 2015-2018. 61
32441625 2020
24
Screening of a library of recombinant Schistosoma mansoni proteins with sera from murine and human controlled infections identifies early serological markers. 61
32524140 2020
25
Structural and functional insights into macrophage migration inhibitory factor from Oncomelania hupensis, the intermediate host of Schistosoma japonicum. 61
32484230 2020
26
Parallelized Impedance-Based Platform for Continuous Dose-Response Characterization of Antischistosomal Drugs. 61
32510834 2020
27
LncRNAs in molluscan and mammalian stages of parasitic schistosomes are developmentally-regulated and coordinately expressed with protein-coding genes. 61
32131676 2020
28
Screening for infection in unaccompanied asylum-seeking children and young people. 61
32094246 2020
29
CCR5 and CCR5Δ32 in bacterial and parasitic infections: Thinking chemokine receptors outside the HIV box. 61
32212259 2020
30
Barbatic acid from Cladia aggregata (lichen): Cytotoxicity and in vitro schistosomicidal evaluation and ultrastructural analysis against adult worms of Schistosoma mansoni. 61
31935486 2020
31
DNA hypermethylation during tuberculosis dampens host immune responsiveness. 61
32125282 2020
32
Plasma Endotoxin Levels Are Not Increased in Schistosoma mansoni-Infected Women without Signs or Symptoms of Hepatosplenic Disease. 61
32124718 2020
33
Evaluation of morbidity in Schistosoma mansoni-positive primary and secondary school children after four years of mass drug administration of praziquantel in western Kenya. 61
32539826 2020
34
Metabolic profiles of Oncomelania hupensis after molluscicidal treatment: carbohydrate metabolism targeted and energy deficiency. 61
32533936 2020
35
Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment. 61
32571433 2020
36
Six rounds of annual praziquantel treatment during a national helminth control program significantly reduced schistosome infection and morbidity levels in a cohort of schoolchildren in Zimbabwe. 61
32569278 2020
37
Achieving Elimination as a Public Health Problem for Schistosoma mansoni and S. haematobium: When Is Community-Wide Treatment Required? 61
31829414 2020
38
When, Who, and How to Sample: Designing Practical Surveillance for 7 Neglected Tropical Diseases as We Approach Elimination. 61
32529261 2020
39
Sonographic findings of pinpoint hyperechoic foci in the small intestine, liver, and mesenteric lymph nodes are indicative of canine Heterobilharzia americana infection. 61
32535944 2020
40
Accuracy of real-time polymerase chain reaction to detect Schistosoma mansoni - infected individuals from an endemic area with low parasite loads. 61
32484122 2020
41
Efficacy and safety of single 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis. 61
32569275 2020
42
Urogenital schistosomiasis detected in sub-Saharan African migrants attending primary healthcare consultations in Paris, France: a 14-year retrospective cohort study (2004-2017). 61
32006177 2020
43
Assessment of knowledge, attitude and practices and the analysis of risk factors regarding schistosomiasis among fishermen and boatmen in the Dongting Lake Basin, the People's Republic of China. 61
32487266 2020
44
Adjuvant-free schistosome cathepsin L3 is an efficacious schistosomiasis vaccine-comment on Huang et al.: Characteristics and function of cathepsin L3 from Schistosoma japonicum. 61
32507901 2020
45
Identification of annotated bioactive molecules that impair motility of the blood fluke Schistosoma mansoni. 61
32531750 2020
46
Neglected Tropical Diseases in the Context of Climate Change in East Africa: A Systematic Scoping Review. 61
32228798 2020
47
Correction to: Schistosomiasis-from immunopathology to vaccines. 61
32519147 2020
48
Reliability of heterophyid antigens in heterologous protection against human schistosomiasis. 61
32508409 2020
49
The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis. 61
32554084 2020
50
A Systematic Review and Meta-Analysis to assess the association between Urogenital Schistosomiasis and HIV/AIDS Infection. 61
32542045 2020

Variations for Schistosoma Mansoni Infection, Susceptibility/

Expression for Schistosoma Mansoni Infection, Susceptibility/

Search GEO for disease gene expression data for Schistosoma Mansoni Infection, Susceptibility/.

Pathways for Schistosoma Mansoni Infection, Susceptibility/

GO Terms for Schistosoma Mansoni Infection, Susceptibility/

Sources for Schistosoma Mansoni Infection, Susceptibility/

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....